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Standard methods used to estimate HIV-1 population diversity are often resource intensive (e.g., single
genome ampliﬁcation, clonal ampliﬁcation and pyrosequencing) and not well suited for large study
cohorts. Additional approaches are needed to address the relationships between intraindividual HIV-1
genetic diversity and 2 disease. With a small cohort of individuals, we validated three methods for
measuring diversity: Shannon entropy and average pairwise distance (APD) using single genome
sequences, and counts of mixed bases (i.e. ambiguous nucleotides) from population based sequences. In
a large cohort, we then used the mixed base approach to determine associations between measure
HIV-1 diversity and HIV associated disease. Normalized counts of mixed bases correlated with Shannon
Entropy at both the nucleotide (rho¼0.72, p¼0.002) and amino acid level (rho¼0.59, p¼0.015), and
APD (rho¼0.75, p¼0.001). Among participants who underwent neuropsychological and clinical
assessments (n¼187), increased HIV-1 population diversity was associated with both a diagnosis of
AIDS and neuropsychological impairment.
Published by Elsevier Inc.Introduction
HIV-1 is usually transmitted as a small number of relatively
homogenous variants, but exists within an infected individual as a
highly diverse viral population (Keele et al., 2008; Wolinsky et al.,
1996b; Wood et al., 2009). Additionally, viral RNA model systems
suggest that maintaining a highly diverse viral population may
provide an adaptive advantage and can alter virulence (Domingo
et al., 1997; Pfeiffer and Kirkegaard, 2005; Pfeiffer and Kirkegaard,
2006; Vignuzzi et al., 2006). Additional study is needed to betterInc.
ia San Diego, 9500 Gilman
858 552 7445.
arch, University of Californiacharacterize both HIV-1 diversity within an individual and the
mechanistic underpinnings of HIV-1 virulence.
Standard methods used to estimate HIV-1 population diversity
in the setting of natural infection are resource intensive (e.g. single
genome ampliﬁcation, clonal ampliﬁcation, pyrosequencing and
heteroduplex assay), which likely explains why past studies that
examined intra-individual HIV-1 population diversity and disease
progression relied on relatively small cohorts (range n¼6–44)
(Delwart et al., 1997; Ganeshan et al., 1997; Markham et al.,
1998; Poon et al., 2007; Ross and Rodrigo, 2002; Shankarappa
et al., 1999a; Strunnikova et al., 1998; Wolinsky et al., 1996a). To
enhance the study of HIV-1 diversity, we validated a method for
estimating HIV-1 population diversity that relies on HIV-1 pol
sequence data generated as part of standard clinical care
(Cornelissen et al., 2007; Kouyos et al., 2011; Poon et al., 2007).
Speciﬁcally, this study investigated how ambiguous or ‘mixed bases’
contained in population-based HIV-1 pol sequences were associated
G.K. Hightower et al. / Virology 433 (2012) 498–505 499with viral population diversity and neurocognitive impairment. After
validating this approach, we studied the relationship between
intra-individual HIV-1 population diversity and disease in a large
cohort of clinically well-characterized HIV-1 infected individuals
who underwent neuromedical and comprehensive neuropsycholo-
gical testing examinations.Results
Study participants
Participants from the San Diego Primary Infection cohort
(n¼16), selected to investigate the use of mixed base indices,
were mostly white men in their early thirties. The three major
reasons participants enrolled in the Primary Infection Cohort did
not meet inclusion criteria were: (1) the absence of longitudinal
samples to assess the potential of dual infection, (2) the absence
of single genome and population-based sequences performed on
blood samples collected within a month of each other, and (3)
presence of HIV-1 dual infection as deﬁned by previously pub-
lished methods (Cornelissen et al., 2007).
The participants from the CHARTER cohort (n¼187) selected to
investigate the relationship between HIV-1 population diversity
and disease were in large part black (49%) men (80%) in their early
forties and 23% were receiving antiretroviral therapy at the time of
sampling. Median blood and CSF HIV RNA levels were 4.6 and
3.6 log10copies/ml, 43% had an AIDS diagnosis, and the median
current and nadir CD4 counts were 362 and 251 cells/ul (Table 1).
Drug resistance mutations were not common; M184V and K103N
were the twomost prevalent. The M184V mutation was detected in
8 blood samples (5%) and 7 CSF samples (4%). The K103N mutation
was detected in 13 blood samples (7%) and 14 CSF samples (8%).
Mixed base counts and evaluating intra-individual
HIV-1 diversity
Using single genome and population-based sequences generated
from San Diego Primary Infection Cohort participants, we measured
and compared Shannon Entropy of nucleotide sequences and APD
to two mixed base indices structured to estimate nucleotide
diversity (Total Mixed Base Index (TM-Index) and Synonymous
Mixed Base Index (SM-Index)). Also, Shannon Entropy of amino acid
sequences was compared to the mixed base index structured toTable 1
CHARTER participant demographics and clinical characteristics.
Variable (N¼187) Median (IQR) or %
Male 80%
Black 49%
Hispanic 8%
White 41%
Age (years) 42 (37–47)
Estimated duration of infection (months) 113 (39–173)
HIV RNA CSF (log10copies/ml) 3.56 (3.14–4.05)
HIV RNA Blood (log10copies/ml) 4.55 (4.11–4.88)
Current CD4 (cells/ul) 362 (224–532)
Nadir CD4 (cells/ul) 251 (141–378)
AIDS 43%
Blood Total Mixed Base Index 0.013 (0.009–0.018)
Blood Synonymous Mixed Base Index 0.010 (0.005–0.014)
Blood Residue Mixed Base Index 0.003 (0.002–0.005)
CSF Total Mixed Base Index 0.014 (0.008–0.019)
CSF Synonymous Mixed Base Index 0.009 (0.005–0.014)
CSF Residue Mixed Base Index 0.003 (0.002–0.005)
Values are reported as percentages or medians with interquartile (IQR) ranges in
parentheses.measure amino acid diversity (Residue Mixed Index (RM-Index)).
There was an average of 26 single genome sequences per San Diego
Primary Infection participants (range 18–32). In brief, all mixed base
indices strongly correlated with other measures of viral population
diversity (Figs. 1 and 2). Speciﬁcally, the TM-Index correlated with
both Shannon Entropy (nucleotide) (rho¼0.76, p¼0.001) (Fig. 1a)
and with APD (rho¼0.80, po0.001) (Fig. 2a). The SM-Index also
correlated with both Shannon Entropy (nucleotide) (rho¼0.72,
p¼0.002) (Fig. 1b) and with APD (rho¼0.75, p¼0.001) (Fig. 2b).
The RM-Index correlated with Shannon Entropy (amino acid)
(rho¼0.59, p¼0.015) (Fig. 1c).HIV-1 population diversity, AIDS and neuropsychological
performance
Using population-based HIV-1 pol sequence data, AIDS diag-
nosis and standard classiﬁcations of neurocognitive status fromFig. 1. Comparing Shannon Entropy to mixed base indices. Legend: For partici-
pants with both single genome and population-based sequences, we measured
and compared Shannon Entropy to mixed base indices structured to estimate
nucleotide and amino acid diversity. Shannon Entropy of nucleotide sequences
correlated with the (A) Total Mixed Base Index (rho¼0.76, p¼0.001) and
(B) Synonymous Mixed Base Index (rho¼0.72, p¼0.002) and (C) Residue Mixed
Index (rho¼0.59, p¼0.015).
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models that, where appropriate, included HIV RNA levels in CSF
and blood, duration of infection, current and nadir CD4, ART
history and co-morbidity status (incidental, contributing, con-
founding). We found a diagnosis of AIDS was independently
associated with: (i) TM-Indices in blood (blood OR¼2.0,
p¼0.015) and (ii) RM-Index in blood (OR¼6.5, p¼0.018)
(Table 2). A trend for an association between AIDS diagnosis with
the SM-Index in blood was also observed (OR¼1.8, p¼0.067). In
modeling neuropsychological impairment, nadir CD4 was initially
included but eventually excluded because current CD4 was aFig. 2. Comparing average pairwise distance (APD) to mixed base indices. Legend:
For participants with both single genome and population-based sequences,
we measured and compared APD to mixed base indices structured to estimate
nucleotide diversity. APD correlated with the (A) Total Mixed Base Index (rho¼0.80,
p¼0.002) and (B) Synonymous Mixed Base Index (rho¼0.75, po0.001).
Table 2
Multivariable regressions modeling AIDS.
Model A: AIDS as a function of Blood Total Mixed Bas
history
Estimate S
Blood Total Mixed Base Index 0.666 0
Infection duration (years) 0.103 0
Blood plasma VL (log10) 0.669 0
ART history (current use) 3.046 0
ART history (past use) 0.901 0
Model B: AIDS as a function of Plasma Residue Mixed
ART history
Estimate
Blood Residue Mixed base Index 1.865
Infection duration (years) 0.123
Blood Plasma VL (log10) 0.685
ART history (current use) 2.886
ART history (past use) 0.765
Variables that are independently signiﬁcant at po0.05stronger predictor of impairment. Concerning neuropsychological
impairment, we found that it was independently associated with
the TM-index in blood (OR¼1.9, p¼0.01) and RM-Index in blood
(OR¼11.4, p¼0.001) (Table 3). There was also a trend for the CSF
TM-Index (p¼0.08) to be associated with neuropsychological
impairment. For all of these models, the association between
viral diversity and neurocognitive impairment was independent
of diagnosed comorbid dieases, as determined by ‘‘Frascati’’
criteria (Antinori et al., 2007).
Intra-individual HIV-1 diversity and viral dynamics
in blood and CSF
We further clariﬁed the relationship between HIV diversity and
the sampled compartments. In every case, HIV-1 population diver-
sity in blood plasma correlated with diversity in the CSF for all
mixed base indices (Fig. 3a–c). In addition, for most individuals, the
RM-Index was higher for viral populations derived from the CSF
than for blood (0.004 vs. 0.037, p¼0.059), but this was not observed
for the TM-Index (CSF 0.0143 vs. blood 0.0137, p¼0.115) and SM-
Index (CSF 0.010 vs. blood 0.010, p¼0.263). These ﬁndings were not
explained by pleocytosis, as deﬁned by 45 white blood cells/ml of
CSF(Smith et al., 2009). The correlation between blood TM-index
and CSF TM-Index did not differ between participants with or
without pleocytosis (rho¼0.641 vs. rho¼0.728, p¼0.321). When
we examined nucleotide diversity in blood and CSF in relation to
time, we found that the duration of infection had linear relation-
ships with both blood TM-index (po0.001) (Fig. 4a) and blood SM-
Index (po0.001) (Fig. 4b). In contrast, the relationship between
duration of infection and amino acid diversity in blood, as measured
by the RM-Index, was best described by quadratic regression
(p¼0.07), where the RM-Index steadily increased until approxi-
mately year 12 of infection and then steadily declined (Fig. 4c).
Comparing cost and time
Using population-based HIV-1 pol sequences to investigate HIV
viral population diversity in both blood and CSF for the CHARTER
cohort instead of SGS or UDS saved approximately $298,078
($390,830 for SGS and $298,078 for UDS) and 2431 h of labor
(14,586 h for SGS and 2431 h for UDS). The costs saving are based
on the estimated cost per sample of $278 for population-based
sequencing, $1323 for SGS, and $1075 for UDS. The labor savingse Index, infection duration, plasma VL and ART
td. error Adjusted OR p-value
.275 1.95 0.0154
.036 1.11 0.0039
.267 1.95 0.0121
.604 21.0 o0.0001
.467 2.46 0.0539
Base Index, infection duration, plasma VL and
Std. error Adjusted OR p-value
0.788 6.46 0.0179
0.035 1.13 0.0004
0.268 1.98 0.0107
0.594 17.9 o0.0001
0.465 2.15 0.0998
are in bold.
Table 3
Multivariable regressions modeling neuropsychological performance.
Model A: Neurocognitive impairment as a function of Blood Total Mixed Base Index, infection duration, AIDS, current CD4, comorbidity status and ART History
Estimate Std. error Adjusted OR p-value
Blood Total Mixed Base Index 0.649 0.256 1.9 0.013
Infection duration (years) 0.105 0.037 0.90 0.004
Current CD4 count 0.015 0.01 0.99a 0.140
AIDS 0.758 0.493 0.47 0.123
Comorbidity (confounding) 2.36 0.541 10.6 o0.001
Comorbidity (contributing) 1.01 0.406 2.8 0.013
ART history (current use) 1.06 0.569 2.9 0.062
ART history (past use) 0.066 0.437 1.1 0.879
Model B: Neurocognitive impairment as a function of Blood Residue Mixed Base Index, infection duration, AIDS, current CD4, comorbidity status and ART history
Estimate Std. error Adjusted OR p-value
Blood Residue Mixed Base Index 2.43 0.759 11.4 0.001
Infection duration (years) 0.088 0.035 0.92 0.013
Current CD4 count 0.015 0.010 0.98a 0.136
AIDS 0.891 0.507 0.41 0.079
Comorbidity (confounding) 2.46 0.551 11.7 o0.001
Comorbidity (contributing) 1.08 0.413 2.9 0.009
ART history (current use) 1.03 0.585 2.8 0.077
ART history (past use) 0.037 0.452 1.0 0.935
Variables that are independently signiﬁcant at po0.05 are in bold.
a Odds ratio (OR) per 10 units increase in CD4 count.
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population-based sequencing, 42 h for SGS, and 9.5 h for UDS.Discussion
This study investigated the use of a novel approach for
measuring intra-host viral population diversity and the relation-
ship between viral genetic diversity and HIV-1 disease state.
The approach evaluated HIV-1 population diversity by providing
a normalized count of mixed bases from population-based
sequences. Three different measures of nucleotide variability
were evaluated: Total Mixed Base Index (TM-Index), Synonymous
Mixed Base Index (SM-Index) and amino acid or Residue Mixed
Base Index (RM-Index). Since the mixed base methods required
only one population-based sequence to evaluate population
diversity, they were well suited to analyze HIV-1 RNA populations
in blood and CSF from a relatively large study cohort (n¼187).
The time and cost associated with performing standard meth-
ods of evaluating HIV-1 genotypic population diversity likely
explain why previous studies have used relatively small sample
sizes (Delwart et al., 1997; Ganeshan et al., 1997; Markham et al.,
1998; Poon et al., 2007; Ross and Rodrigo, 2002; Shankarappa
et al., 1999a; Strunnikova et al., 1998; Wolinsky et al., 1996a). To
address this methodological limitation, we investigated the use of
population-based sequences and a normalized count of mixed
bases to evaluate HIV-1 population diversity. We found the mixed
base method was comparable to Shannon Entropy and APD, two
widely used methods for measuring HIV-1 population diversity.
This approach builds on previous studies that have used the
occurrence of mixed bases in population-based sequences to
screen for HIV-1 dual infection (Cornelissen et al., 2007) and as
a site-speciﬁc marker of variation (Kouyos et al., 2011; Poon et al.,
2007). Using the normalized mixed base approach, we found that
increased HIV-1 population diversity was associated with: AIDS
(TM-Index measured in blood and RM-Index in blood) and
neuropsychological impairment (TM-Index measured in blood and
RM-Index in blood). These associations between HIV-1 population
diversity and disease state, suggest that HIV-1 virulence is mostlikely associated with the capacity of a viral population to maintain
genetic diversity and not simply a speciﬁc and predominant
genotypic variant, although the exact underlying mechanism for
this remains unclear. For complex phenotypes such as neuropsy-
chological impairment, HIV-1 variants may work in a coordinated
manner to cause disease. As a hypothesis, neuropathogenesis may
require multiple distinct viral variants. For example, one variant
with high viral replication in the CNS may trigger inﬂammation and
prime other cells for infection, while a second variant replicates in a
speciﬁc tissue that disrupts a process essential for optimal neurop-
sychological function. This hypothesis builds on studies of polio-
virus that link viral diversity and pathogenesis (Bushell and Sarnow,
2002; Pfeiffer and Kirkegaard, 2005; Pfeiffer and Kirkegaard, 2006;
Vignuzzi et al., 2006), but these and other hypotheses need to be
tested to better characterize the mechanisms of HIV-1 virulence in
relation to viral population diversity.
In this study, we also observed a steady increase in genetic
variability (i.e. mixed bases) at synonymous sites over time, as
measured by the SM-Index, in both CSF and blood plasma.
In contrast, diversity at nonsynonymous sites (i.e. amino acid
residues), as measured the RM-Index, in blood plasma steadily
increased until about year 12 of duration of infection and then
steadily declined. The observed rise and decline in diversity at
nonsynonymous sites in blood likely results from the diminishing
capacity of the immune system or ﬁxation of cytotoxic
T-lymphocyte immune mediated escape mutations over time
(Allen et al., 2005; Borrow et al., 1997; Friedrich et al., 2004;
Price et al., 1997). While this pattern was seen in the blood,
diversity at nonsynonymous sites in the CSF continued to steadily
increase over time, suggesting that immune and potentially other
selection pressures in the CNS differ from those in the blood.
Further, these changes in mixed base indices in regards to duration of
infection are likely to be more pronounced during chronic infection
given the overall changes in viral population diversity over the
natural history of HIV infection (Kouyos et al., 2011; Shankarappa
et al., 1999b).
To further investigate intra-individual differences between
HIV-1 variants circulating in the blood and CSF, we compared
measurements of HIV-1 population diversity in the blood and CSF.
Fig. 3. HIV-1 population diversity in blood and CSF. Legend: HIV-1 population
diversity in blood correlated with diversity in CSF as measured by the (A) Total
Mixed Base Index (spearman rho¼0.68, po0.001), (B) Synonymous Mixed Base
Index (spearman rho¼0.70, po0.001) and (C) Residue Mixed Index (spearman
rho¼0.62, po0.001).
Fig. 4. HIV-1 population diversity in blood with relation to time. Legend: Duration
of infection had linear relationships with viral population diversity in blood as
measured by the (A) Total Mixed Base Index (po0.001) and (B) Synonymous
Mixed base Index (po0.001), but the trend was quadratic for the (C) Residue
Mixed Index (p¼0.07).
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CSF than blood plasma, suggesting that HIV-1 in the CNS likely
originated from multiple variants and not a consequence of
monoclonal ampliﬁcation. Additionally, pleocytosis, a marker of
lymphocyte trafﬁcking from the blood to the CSF, was not
associated with changes in viral diversity in the CSF. This lack of
difference may be related to the high proportion of cases
demonstrating pleocytosis in this cohort (118/174; 68%), and is
consistent with the relatively high CSF viral loads observed, which
was a condition of eligibility in this study. Since it is not feasible
to amplify virus at low levels, these patients were excluded from
the study, and may represent a selection bias in the investigation.
In this study, neuropsychological impairment was negatively
correlated with reported duration of infection, which was unex-
pected given that loss of CD4þ T lymphocytes is associated with
greater duration of infection (O’Brien et al., 1997; Strain et al.,
2005), and lower CD4 counts have been associated with neurop-
sychological impairment (Antinori et al., 2007; Lentz et al., 2009;
Tozzi et al., 2007). This may point to another limitation of the
study, and is most likely a bias in the study design and cohort,
which concerns factors like cross-sectional design, survival bias
and differences in antiretroviral therapy use, effectiveness andduration. An obvious example of survival bias for all HIV cohorts
is that HIV-infected people who live longer and with less disease
would be more likely to participate in study cohorts. This factor is
further obscured by differential use of antiretroviral therapy and
its effectiveness. A prospective longitudinal study would most
likely be needed to provide additional and more conclusive
insight, especially in relation to duration of infection, which was
only by self-report in the CHARTER cohort.
The present study was also limited by the investigating of only
the HIV-1 pol coding region. Viral diversity in other coding
regions, like env, are likely to be important in neuropathogenesis
(Dunfee et al., 2007; Harrington et al., 2009; Pillai et al., 2006),
and this should be evaluated in future studies. However, inves-
tigating pol did allow us to evaluate resistance-associated muta-
tions in the context of HIV-1 diversity and disease, but the low
prevalence of these mutations in our study population, speciﬁ-
cally M184V and K103N, prevented meaningful conclusions.
An additional limitation of this study is that we did not screen
for dual infections among CHARTER cohort participants included
in the analysis of neuropsychological impairment. It is likely that
some participants in the CHARTER cohort were dually infected,
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and disease progression (Kouyos et al., 2011; Pacold et al.).
Although the mixed base approach is less resource intensive than
other methods used to evaluate diversity, it does not allow for the
identiﬁcation or quantiﬁcation of speciﬁc variants and this may
be necessary for characterizing dual infection or speciﬁc neuro-
virulent phenotypes. Future studies will be needed to evaluate
these issues.
Measuring mixed bases in population-based sequences can be
used as less expensive and time-consuming method to evaluate
HIV-1 population diversity, and is a method especially suited for
evaluating intra-host diversity for large cohorts. Using this
approach to investigate diversity in a relatively large well-deﬁned
cohort, we demonstrate that HIV-1 population diversity is posi-
tively associated with disease, speciﬁcally AIDS and neuropsycho-
logical impairment.Methods
Ethics statement
The Human Research Protection Program of the University of
California San Diego approved the use of all participant data and
samples. In accordance with the Human Research Protection
Program of the University of California, informed consistent was
provided by all study participants.
Study design
Our study utilized two different participant cohorts. From the
UCSD Primary Infection Cohort, we used blood samples to
investigate if mixed base counts provide reliable estimates of
HIV-1 diversity. From the CNS HIV Antiretroviral Therapy Effects
Research (CHARTER) Cohort, we used blood and cerebrospinal
ﬂuid (CSF) samples to investigate the relationship between intra-
host HIV-1 population diversity and disease.
Participants enrolled in the UCSD Primary Infection Cohort
were included in this study if they were antiretroviral naive, had
two or more longitudinally collected blood samples, and single
genome and population-based sequences were available from
blood samples collected within a month of each other. All
participants in the cohort were enrolled within 70 day of the
estimated date of infection, as previously described (Morris et al.,
2010). Blood samples from dates at which an individual was
suspected of dual infection with previously published criteria
were excluded (Cornelissen et al., 2007). Using a longitudinal
cohort allowed us to screen for dual infections and decrease any
irregularities in our validation studies that might be attributable
to dual infection. When two or more sample dates were eligible
from the same participant, the last date was used. All participants
enrolled in the CHARTER Cohort were included in this study if
viral loads were high enough (500 copies/ml) to generate
population-based sequences of HIV-1 pol, as described below.
CHARTER participants received neuromedical, neuropsychological,
and laboratory examinations. Standardized neuropsychological
assessments tested seven ability domains (learning, delayed recall,
verbal ﬂuency, processing speed, attention/working memory, abstrac-
tion/executive functioning, motor speed), as previously described
(Woods et al., 2004). Results were summarized using global ratings
that ranged from 1 (above average) to 9 (severely impaired) with a
global score of 5 or higher used to categorize participants as impaired
(Antinori et al., 2007; Heaton et al., 2010). Also, for each participant,
the ‘‘Frascati’’ criteria (incidental, contributing, confounding) were
used to classify non-HIV-1 related conditions that increase risk for
neurocognitive impairment (Antinori et al., 2007). Infectionduration in this cohort was available only as self-reported informa-
tion. Among CHARTER participants, AIDS diagnosis was based on
the 1993 Centers for Disease Control guidelines (www.cdc.gov/hiv/
resources/guidelines).
Sample collection and processing
For both cohorts, blood plasma was collected by venipucture
and CSF by lumbar puncture, and stored at 80 1C. For blood
samples collected from participants enrolled in the UCSD Primary
Infection Cohort, HIV RNA was extracted using the QIAamp Viral
RNA Mini Kit (Qiagen, Hilden, Germany) per manufacturer’s
instructions. For blood and CSF samples collected from CHARTER
Cohort participants, HIV RNA was extracted using the ViroSeq
v.2.0 HIV genotyping system (Applied Biosystems, Foster City,
CA, USA).
Single genome ampliﬁcation and sequencing
Extracted HIV RNA was used to generate cDNA using random
decamers and the RETROscript kit (Ambion, Applied Biosystems,
Foster City, CA, USA) per manufacturer’s instructions. The ﬁrst
round of nested PCR was performed with 10 uL of diluted cDNA
template and 40 uL of reaction mix, which included the following
outer primer set (CI-Pol 50, 3RT 30). The second round PCR, was
performed with 5 uL of the ﬁrst round product and 45 uL of
reaction mixture which included the following inner primer set
(5RT 50, 3RT 30). Reactions were performed in parallel on a 96-well
plate, and the second-round products were visualized to ensure
no more than 30% of the reaction wells were positive, as
previously described (Butler et al., 2009).
Population-based pol sequencing
The ViroSeq HIV genotyping system (Ambion Applied Biosys-
tems) was used for population-based HIV-1 pol sequencing per
manufacturer’s instructions. Following cDNA synthesis, polymer-
ase chain reaction (PCR) ampliﬁcation was used to generate a
1500-bp amplicon including the entire protease and ﬁrst two
thirds of the reverse transcriptase. The resulting PCR product was
sequenced using the ABI 3100 Genetic Analyzer, sequences were
manually edited and resistance associated mutations were deter-
mined using the ViroSeq genotyping software.
Evaluating and comparing measures of intra-individual
HIV-1 diversity
Using HIV RNA extracted from the blood samples of participants
enrolled in the UCSD Primary Infection Cohort, we evaluated HIV-1
population diversity with three different methods: (1) Shannon
Entropy using single genome, (2) average pairwise distance (APD)
using single genome sequences and (3) counts of mixed bases (i.e.,
ambiguous nucleotides) in population-based sequences. Mixed
bases were deﬁned as double peaks in the electropherograms of the
HIV-1 pol sequences that were identiﬁed by the basecaller Viroseq
program.
A batch ﬁle implemented in HyPhy (Kosakovsky Pond, Frost,
and Muse, 2005) was used to provide a count of total mixed bases,
synonymous mixed bases and nonsynonymous mixed bases in
population-based pol sequences. Each count was divided by
sequence length to provide a normalized index: Total Mixed Base
Index (TM-Index), Synonymous Mixed Base Index (SM-Index) and
Amino Acid Residue Mixed Base Index (RM-Index). In summary,
the TM-Index was simply the count of all mixed nucleotide bases in
each HIV-pol sequence divided by the sequence length. The SM-Index
was the count of only those mixed bases that could not change the
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length, while the RM-Index considered only those bases that could
change the protein sequence, i.e. non-synonymous change. Shannon
Entropy was measured for nucleotide sequences and amino acid
sequences using the HIV Los Alamos National Laboratory (LANL)
Entropy-One tool (http://www.hiv.lanl.gov, accessed April 2010).
For each participant’s set of single genome sequences, Entropy-
One results were summarized as the number of sites with a
Shannon Entropy value Z0.3 divided by the number of positions
in the alignment. APD was measured by analyzing participant
speciﬁc single genome sequences with HyPHy software using the
Tamura-Nei 93 model (TN93) (Tamura and Nei, 1993), as pre-
viously described (Smith et al., 2009).
Estimating cost and time
Estimates of the comparative costs and labor required for
population-based sequencing, single genome sequencing (SGS)
and ultra deep sequencing (UDS) were based on previously
published analysis (Bushman et al., 2008). The estimated and
anticipated sequencing costs for measuring HIV-1 population
diversity were calculated from the costs of reagents, disposable
materials, kits and sequencing runs. The estimated and antici-
pated labor was calculated as the labor time plus instrument time
were required to perform sequencing.
Statistical analysis
All tests were two-sided and interpreted at 5% signiﬁcance
level. Tests for associations between two continuous variables
were performed using Spearman rank correlation. Logistic regres-
sion analyses were used to investigate the relationships between
HIV-1 diversity (measured by the TM-Index, SM-Index and RM-
Index) and AIDS diagnosis and between HIV-1 diversity and
neuropsychological impairment. Additional variables considered
in multivariable logistic regression analyses, where appropriate,
included HIV RNA levels in CSF and blood, duration of infection,
current and nadir CD4, and ART history. The model investigating
neuropsychological impairment also controlled for AIDS and non-
HIV-1 related conditions that increase risk for neurocognitive
impairment. The odds ratios were calculated for a 0.01 unit
increase in each mixed base index.Acknowledgments
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